RxDoctor Payments Data

Holly Anderson, MD

Family Medicine · Provo, UTNPI 1609239946

Payments from drug & device makers

$669in general payments, 2019–2025

Across 30 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$272
  • Boehringer Ingelheim$188
  • Abbott$41
  • Dexcom, Inc.$20
  • Treace Medical Concepts, Inc.$19
  • Gilead$17
  • plus $112 from 8 others

What the payments were for

  • Food & beverage$669100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$669 in reported general payments places this provider in the 55th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$33,624
Medicare patients
98
Services billed
624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide37$38,379
JardianceEmpagliflozin15$19,729
OzempicSemaglutide14$13,876
EliquisApixaban12$8,909
FarxigaDapagliflozin Propanediol12$6,389
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,942
Bupropion XlBupropion Hcl42$1,897
Levothyroxine Sodium143$1,689
Atorvastatin Calcium166$1,625
SynthroidLevothyroxine Sodium14$1,614
Celecoxib12$1,540
Rosuvastatin Calcium94$1,298
HumalogInsulin Lispro11$1,162
Metformin Hcl83$1,102
Estradiol32$1,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$188$19,72915 claims
Novo NordiskOzempic$13$13,87614 claims
PfizerEliquis$12$8,90912 claims
AstraZenecaFarxiga$11$6,38912 claims
AbbVieSynthroid$272$1,61414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 928 family medicine providers in Utah.

Other family medicine in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →